UBS Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

UBS Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-90,000	Closed	-$49K	–	8510
2016 Q3	$49K	Hold	90,000	–	–	﹤0.01%	5549
2016 Q2	$52K	Hold	90,000	–	–	﹤0.01%	5501
2016 Q1	$131K	Hold	90,000	–	–	﹤0.01%	4786
2015 Q4	$288K	Hold	90,000	–	–	﹤0.01%	4385
2015 Q3	$563K	Buy	+90,000	New	+$841K	﹤0.01%	3803
2015 Q1	–	Sell	-1,300	Closed	-$7K	–	10230
2014 Q4	$7K	Buy	+1,300	New	+$6.65K	﹤0.01%	8782

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

UBS Group's NWBO Position: Q4 2016 in Review

UBS Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 9,012 shares — an estimated $5K sold.

UBS Group first reported a position in NWBO in Q4 2014 and held it in 8 quarters. The position peaked at $130K in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

UBS Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
UBS Group sold 9,012 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $5K.
UBS Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2014 and held it in 8 quarters.
UBS Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $130K in Q2 2015.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.